A Gu, Shan Yuezhan, Huo Huasong, Ding Chao, Sun Caixia
Department of Gastrointestinal Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, China.
Department of Neurosurgery, The First Hospital of Jilin University, Changchun, China.
Appl Bionics Biomech. 2022 Jun 15;2022:3655225. doi: 10.1155/2022/3655225. eCollection 2022.
The CT scan is the best common screening test for pancreatic cancer recurrence after surgery. The goal of our meta-analysis was to assess the diagnostic accuracy of 18F-FDG PET/CT for pancreatic cancer recurrence.
We examined PubMed and Embase for suitable papers between 2009 and 2022. The researchers considered studies that looked at the diagnostic usefulness of 18F-FDG PET/CT in identifying local and/or distant disease recurrence throughout the follow-up following pancreatic cancer resection. The Quality Assessment of Diagnostic Performance Studies-2 (QUADAS-2) method was used to evaluate the quality of each study. For each of the publications included, two researchers extracted data independently. The extracted data included general data (authors, year of publication), literature characteristics (country, type of literature, and design of study), characteristics of the patient (patients' number, mean or median age, and treatment regimen), and technical aspects (scanner, injection activity, and image analysis).
The analysis includes 7 trials with a total of 263 patients. The sensitivity and specificity of 18F-FDG PET/CT in detecting recurrent pancreatic cancer following definitive treatment were 0.89 (95 percent CI: 0.83-0.93) and 0.88 (95 percent CI: 0.72-0.96), respectively, according to the pooled estimates. PET/CT performed well in the diagnosis of recurrent pancreatic cancer, with an AUC of 0.94. (0.91-0.95).
18F-FDG PET-CT was found to be a reliable detection method in recurrent pancreatic tumor.
CT扫描是术后胰腺癌复发最常用的筛查检查。我们进行荟萃分析的目的是评估18F-FDG PET/CT对胰腺癌复发的诊断准确性。
我们检索了2009年至2022年期间PubMed和Embase上的相关文献。研究人员纳入了观察18F-FDG PET/CT在胰腺癌切除术后随访期间识别局部和/或远处疾病复发诊断效用的研究。采用诊断性能研究质量评估-2（QUADAS-2）方法评估每项研究的质量。对于纳入的每篇文献，两名研究人员独立提取数据。提取的数据包括一般数据（作者、发表年份）、文献特征（国家、文献类型和研究设计）、患者特征（患者数量、平均或中位年龄以及治疗方案）和技术方面（扫描仪、注射活性和图像分析）。
该分析纳入了7项试验，共263例患者。根据汇总估计，18F-FDG PET/CT在检测确定性治疗后复发性胰腺癌方面的敏感性和特异性分别为0.89（95%CI：0.83-0.93）和0.88（95%CI：0.72-0.96）。PET/CT在复发性胰腺癌的诊断中表现良好，AUC为0.94（0.91-0.95）。
18F-FDG PET-CT被发现是复发性胰腺肿瘤的可靠检测方法。
